Related Experiment Video
Updated: Sep 20, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced
1Eve Topf and National Parkinson Foundation Centers Of Excellence For Neurodegenerative Diseases Research, and Department of Pharmacology, Technion-Faculty of Medicine, Haifa, Israel. youdim@tx.technion.ac.il
Abstract:
There have been numerous hypotheses concerning the etiology and mechanism of dorsal raphe dopaminergic neurodegeneration in Parkinson's disease and its animal models, MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-hydroxydopamine. The advent of cDNA microarray gene expression where expression of thousands of genes can be globally assessed has indicated that mechanism of neurodegeneration by MPTP is a complex cascade of vicious circles. One of these is the alteration of genes associated with iron metabolism, a transitional metal closely associated with inducing the formation of reactive oxygen species and inducing oxidative stress. cDNA gene expression analyses support the established hypothesis of oxidative induced neurodegeneration involving iron deposition in substantia nigra pars compacta (SNPC) parkinsonian brains. The regulation of cellular iron metabolism has been further enhanced by the recent discovery of two iron regulatory proteins, IRP1 and IRP2 which control the level of iron with in the cell. When the cellular level of iron increases IRP2 is degraded by ubiquitination and no further iron accumulates. The reverse occurs when the level of iron is low within the cell. Knock-out IRP1 and IRP2 mice have shown that in latter mice brain iron accumulation precedes the neurodegeneration, ataxia and bradykinesia observed in these animals. Indeed MPTP treatment, which results in iron accumulation in SNCP, abolishes IRP2 with the concomitant increase in alpha-synuclein. Iron chelators such as R-apomorphine and EGCG, which protect against MPTP neurotoxicity, prevent the loss of IRP2 and the increase in alpha-synuclein. The presence of iron together with alpha-synuclein in SNPC may be detrimental for dopaminergic neurons. Since, iron has been shown to cause aggregation of alpha-synuclein to a neurotoxic agent. The use of iron chelators penetrating the blood brain barrier as neuroprotective drugs has been envisaged.
Insights
Iron accumulation in the brain, particularly in the substantia nigra pars compacta, is linked to Parkinson
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Parkinson's disease involves neurodegeneration of dopaminergic neurons.
- MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a common neurotoxin used in Parkinson's disease research.
- Iron metabolism plays a critical role in oxidative stress and neurodegeneration.
Purpose of the Study:
- To investigate the role of iron metabolism in MPTP-induced neurodegeneration.
- To explore the function of iron regulatory proteins (IRPs) in Parkinson's disease models.
- To assess the neuroprotective potential of iron chelators.
Main Methods:
- Gene expression analysis (cDNA microarray) to identify altered genes.
- Studies using knockout mice lacking IRP1 and IRP2.
- MPTP treatment in animal models.
- Administration of iron chelators (R-apomorphine, EGCG).
Main Results:
- MPTP treatment leads to iron accumulation and IRP2 degradation in the substantia nigra pars compacta.
- IRP2 knockout mice exhibit iron accumulation preceding neurodegeneration.
- Iron chelators protect against MPTP neurotoxicity by preventing IRP2 loss and alpha-synuclein increase.
- Iron and alpha-synuclein co-localization in the substantia nigra pars compacta may be neurotoxic.
Conclusions:
- Iron dysregulation is a key factor in MPTP-induced dopaminergic neurodegeneration.
- IRP2 plays a crucial role in regulating cellular iron levels and preventing neurotoxicity.
- Iron chelators show promise as a therapeutic strategy for Parkinson's disease.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview